Tracker › Companies › Passage Bio, Inc.
6 No sign of it. We found no public evidence tying Passage Bio, Inc.'s cuts to AI.
Every tracked 2026 layoff at Passage Bio, Inc., newest first. Scores are 0–100: how strongly the public evidence ties the cuts to AI. Sources are linked on each one.
AI score 6/100 (Minimal) · 80% interval 4–7 · evidence grade D · US · Pharma / Chemicals
Stated reason: As part of its previously announced efforts to review strategic alternatives to maximize shareholder value, on April 28, 2026, Passage Bio, Inc. (the “ Company ”) announced a restructuring of its workforce (the “ Restructuring Plan ”) to decrease its operating expenses by reducing the workforce by approximately 75%. The implementation of the Restructuring Plan should be substantially complete in the second and third …
Why 6: Cost-cutting / efficiency · Drivers: industry AI exposure +0.5
Evidence: SEC filing. Signals: attribution 0.0, primary source 0.0, exec statement 0.0, role exposure 0.653, industry exposure 0.712, AI investment 0.0, contrary evidence 0.0 · typical Health Care & Pharma roles (no roles named)
Headcount basis: not disclosed
Scores are evidence-based estimates from a published model, not findings that AI caused any layoff. Spot something wrong or missing? Tell us.
Other Health Care & Pharma layoffs we track.
Health Care & Pharma · 4,500 workers
Health Care & Pharma · 718 workers
Health Care & Pharma · 628 workers
Health Care & Pharma · 278 workers
Health Care & Pharma · 145 workers
Health Care & Pharma · 130 workers
